Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8736081 | 0.92 | THRB (0.36) | — | |
| SCHEMBL24909869 | 0.79 | LPAR3 (0.33) | FDPS | |
| SCHEMBL7146590 | 0.77 | — | — | |
| SCHEMBL12333935 | 0.75 | LPAR5 (0.40) | GABRR1GABBR2GABBR1PGK1PGK2 | |
| SCHEMBL24909981 | 0.74 | LPAR3 (0.41) | — | |
| SCHEMBL8752659 | 0.73 | — | — | |
| SCHEMBL532287 | 0.71 | LPAR3 (0.50) | FDPSLPAR5 | |
| SCHEMBL18025606 | 0.70 | — | — | |
| SCHEMBL8147108 | 0.70 | — | — | |
| SCHEMBL1973590 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200101102-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | IDERA PHARMACEUTICALS, INC. (US) | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200101102-A1 | TREATMENT OF CANCER USING TLR9 AGONIST WITH CHECKPOINT INHIBITORS | TLR9, TLR3, TLR7 | GABRR1 4352/4885GABBR2 3612/4885GABBR1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.